Poly Medicure Limited

NSEI:POLYMED 주식 보고서

시가총액: ₹254.5b

Poly Medicure 관리

관리 기준 확인 2/4

Poly Medicure CEO는 Himanshu Baid, Sep1995 에 임명되었습니다 의 임기는 29.33 년입니다. 총 연간 보상은 ₹ 171.78M, 33.6% 로 구성됩니다. 33.6% 급여 및 66.4% 보너스(회사 주식 및 옵션 포함). 는 ₹ 29.51B 가치에 해당하는 회사 주식의 11.59% 직접 소유합니다. 29.51B. 경영진과 이사회의 평균 재임 기간은 각각 6.6 년과 8.6 년입니다.

주요 정보

Himanshu Baid

최고 경영자

₹171.8m

총 보상

CEO 급여 비율33.6%
CEO 임기29.3yrs
CEO 소유권11.6%
경영진 평균 재임 기간6.6yrs
이사회 평균 재임 기간8.6yrs

최근 관리 업데이트

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Recent updates

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Dec 28
Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Dec 10
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Nov 02
Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Sep 14
Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Sep 06
After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Aug 14
Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Jul 27
Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Jul 11
Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

May 25
Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

May 12
Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Mar 23
Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Feb 15
Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 16
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Nov 14
Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Oct 24
Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Sep 08
Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Aug 12
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Jul 13
Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Jun 16
Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

Mar 02
Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Feb 14
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Oct 16
Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Sep 28
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Sep 08
Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Jun 25
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Jun 07
A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

May 23
Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Feb 23
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Feb 04
There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 12
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Oct 14
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Poly Medicure (NSE:POLYMED) Could Easily Take On More Debt

Jul 07
Poly Medicure (NSE:POLYMED) Could Easily Take On More Debt

Poly Medicure (NSE:POLYMED) Will Will Want To Turn Around Its Return Trends

Jun 18
Poly Medicure (NSE:POLYMED) Will Will Want To Turn Around Its Return Trends

CEO 보상 분석

Himanshu Baid 의 보수는 Poly Medicure 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹3b

Mar 31 2024₹172m₹58m

₹3b

Dec 31 2023n/an/a

₹2b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹2b

Mar 31 2023₹130m₹55m

₹2b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹1b

Jun 30 2022n/an/a

₹1b

Mar 31 2022₹107m₹49m

₹1b

Dec 31 2021n/an/a

₹1b

Sep 30 2021n/an/a

₹1b

Jun 30 2021n/an/a

₹1b

Mar 31 2021₹92m₹44m

₹1b

Dec 31 2020n/an/a

₹1b

Sep 30 2020n/an/a

₹1b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹62m₹35m

₹959m

Dec 31 2019n/an/a

₹947m

Sep 30 2019n/an/a

₹858m

Jun 30 2019n/an/a

₹719m

Mar 31 2019₹44m₹14m

₹654m

Mar 31 2018₹41m₹14m

₹706m

보상 대 시장: Himanshu 의 총 보상 ($USD 1.99M )은 Indian 시장( $USD 583.85K ).

보상과 수익: Himanshu 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Himanshu Baid (56 yo)

29.3yrs

테뉴어

₹171,781,000

보상

Mr. Himanshu Baid has been the Managing Director of Poly Medicure Limited since September 20, 1995 and serves as Chief Executive Officer. Mr. Baid is an Electronics Engineer and has experience in respect t...

리더십 팀

이름위치테뉴어보상소유권
Himanshu Baid
CEO, MD & Director29.3yrs₹171.78m11.59%
₹ 29.5b
Jugal Baid
Founder & Non Executive Directorno data₹1.43m2.25%
₹ 5.7b
Naresh Vijayvergiya
Chief Financial Officer3.5yrs₹11.21m데이터 없음
Avinash Chandra
Company Secretary & Compliance Officer9.7yrs₹1.88m데이터 없음
Rishi Baid
Joint MD & Executive Directorno data₹166.82m12.33%
₹ 31.4b
Vishal Baid
President of Corporate Sales & Marketing2.8yrs₹18.39m1.66%
₹ 4.2b
P. Rastogi
Assistant Vice President of Finance & Accountsno data데이터 없음데이터 없음
Hemant Bhalla
Senior Vice President of Domestic Sales & Marketingno data₹5.79m데이터 없음
Pankaj Gupta
President of R&Dno data₹5.61m데이터 없음
Manish Sardana
President of Sales & Marketing - Indiano data₹8.61m데이터 없음

6.6yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: POLYMED 의 관리팀은 노련하고 경험 (평균 재직 기간 6.6 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Himanshu Baid
CEO, MD & Director29.8yrs₹171.78m11.59%
₹ 29.5b
Jugal Baid
Founder & Non Executive Director29.8yrs₹1.43m2.25%
₹ 5.7b
Rishi Baid
Joint MD & Executive Director29.8yrs₹166.82m12.33%
₹ 31.4b
Vimal Bhandari
Non-Executive Independent Directorless than a year데이터 없음데이터 없음
Amit Khosla
Non-Executive Independent Director4.6yrs₹1.60m데이터 없음
Devendra Mehta
Non-Executive Independent Chairman19.7yrs₹1.63m데이터 없음
Mukulika Baid
Non-Executive Director10.5yrs₹1.43m3.02%
₹ 7.7b
Sonal Mattoo
Non-Executive Independent Director4.4yrs₹1.45m데이터 없음
Alessandro Balboni
Non-Executive Non Independent Director6.7yrs₹29.90m데이터 없음
Ambrish Mithal
Independent Director2.8yrs₹1.45m데이터 없음

8.6yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: POLYMED 의 이사회는 경험(평균 재직 기간 8.6 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터마지막 업데이트(UTC 시간)
기업 분석2025/01/20 16:46
장 마감 주가2025/01/20 00:00
수익2024/09/30
연간 수익2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
회사 재무10년
  • 손익 계산서
  • 현금 흐름표
  • 대차 대조표
애널리스트 컨센서스 추정치+3년
  • 재무 예측
  • 애널리스트 목표가
시장 가격30년
  • 주식 가격
  • 배당금, 분할 및 액션
소유권10년
  • 최대 주주
  • 내부자 거래
관리10년
  • 리더십 팀
  • 이사회
주요 개발 사항10년
  • 회사 공지 사항

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Poly Medicure Limited 11 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가교육기관
Nitin BhasinAmbit Capital
Karan KhannaAmbit Capital
Sunita VaidyanathanBrics Securities Limited